Mahir Asadli/iStock via Getty Images
- The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Rasonque (daraxonrasib) as a second-line monotherapy treatment for adults with metastatic pancreatic adenocarcinoma.
- The positive opinion was supported by data from the phase 3 RASolute